Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019;26(16):2865-2878.
doi: 10.2174/0929867325666180104153338.

Unfolding Cardiac Amyloidosis -From Pathophysiology to Cure

Affiliations
Review

Unfolding Cardiac Amyloidosis -From Pathophysiology to Cure

Klemens Ablasser et al. Curr Med Chem. .

Abstract

Deposition of amyloidogenic proteins leading to the formation of amyloid fibrils in the myocardium causes cardiac amyloidosis. Although any form of systemic amyloidosis can affect the heart, light-chain (AL) or transthyretin amyloidosis (ATTR) account for the majority of diagnosed cardiac amyloid deposition. The extent of cardiac disease independently predicts mortality. Thus, the reversal of arrest of adverse cardiac remodeling is the target of current therapies. Here, we provide a condensed overview on the pathophysiology of AL and ATTR cardiac amyloidoses and describe treatments that are currently used or investigated in clinical or preclinical trials. We also briefly discuss acquired amyloid deposition in cardiovascular disease other than AL or ATTR.

Keywords: Amyloidosis; desmin; fibrils; heart failure; immunoglobulin light chains; posttranslational modification; pre-amyloid oligomers; transthyretin..

Similar articles

See all similar articles

Cited by 2 articles

MeSH terms

Supplementary concepts

Feedback